Unicycive Therapeutics
UNCY
28 hedge funds and large institutions have $19.1M invested in Unicycive Therapeutics in 2024 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 0 reducing their positions, and 7 closing their positions.
100% more capital invested
Capital invested by funds: $9.52M → $19.1M (+$9.56M)
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
22% more funds holding
Funds holding: 23 → 28 (+5)
0.09% less ownership
Funds ownership: 5.05% → 4.96% (-0.09%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$3.44M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$3.44M |
| 3 |
Walleye Capital
New York
|
+$2.01M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$1.61M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$904K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.32M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$1.1M |
| 3 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$787K |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$501K |
| 5 |
Renaissance Technologies
New York
|
-$16.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Creative Planning
Overland Park,
Kansas
| $4.17K | +$4.11K | +1,023 | New |
|
27
Bank of America
Charlotte,
North Carolina
| $135 | +$44 | +11 | +50% |
|
28
JP Morgan Chase
New York
| $84 | +$56 | +14 | +200% |
|
|
RCM
29
RA Capital Management
Boston,
Massachusetts
| – | -$1.32M | -263,220 | Closed |
|
|
BI
30
BVF Inc
San Francisco,
California
| – | -$1.1M | -220,000 | Closed |
|
|
RA
31
Rosalind Advisors
Toronto,
Ontario, Canada
| – | -$787K | -157,120 | Closed |
|
|
MIM
32
Monashee Investment Management
Boston,
Massachusetts
| – | -$501K | -100,000 | Closed |
|
|
33
Renaissance Technologies
New York
| – | -$16.6K | -3,320 | Closed |
|
|
SRL
34
Scientech Research LLC
Jersey City,
New Jersey
| – | -$5.5K | -1,097 | Closed |
|
|
RWMG
35
Redwood Wealth Management Group
Medford,
New Jersey
| – | -$1.5K | -300 | Closed |
|
UNCY Hedge Fund Activity: Q3 2024 in Review
28 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q3 2024, worth a combined $19.1M — up 100% from $9.52M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new UNCY positions and 7 closed out — a net gain of 5 holders — while 10 added to existing stakes and 0 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $3.44M. The largest seller was RA Capital Management, exiting entirely with an estimated $1.32M sold.
- 28 institutional investors held Unicycive Therapeutics (UNCY) as of Q3 2024, up from 23 in Q2 2024.
- Funds reported $19.1M of Unicycive Therapeutics stock for Q3 2024, up 100% quarter-over-quarter.
- 12 funds opened new Unicycive Therapeutics positions in Q3 2024 and 7 closed out, a net change of +5 holders.
- The largest Unicycive Therapeutics buyer in Q3 2024 was Great Point Partners, an estimated $3.44M added.
- The largest Unicycive Therapeutics seller in Q3 2024 was RA Capital Management, an estimated $1.32M sold.
Based on aggregated 13F filings for Q3 2024.